Nuvation Bio Inc

Nuvation Bio reported second quarter 2026 total revenue of $31.7 million, exceeding analyst estimates, with IBTROZI net product revenue of $23.2 million growing 25% quarter over quarter. Approximately 160 new patients started treatment with IBTROZI, and 85% of these starts were in the first-line setting, up from 30% at launch. The company highlighted IBTROZI's clinical efficacy, including a 90% confirmed overall response rate and a median duration of response of 49.7 months in TKI-naive patients from the TRUST-I study. Nuvation Bio also reported a net loss of $62.8 million, or $0.18 per share, and cash and marketable securities of $661 million as of June 30, 2026. The company completed a $279.1 million convertible debt offering and used $58.7 million to voluntarily prepay outstanding term loans.

Nuvation Bio reported second-quarter total revenue of $31.7 million, including $23.2 million in net U.S. product revenue from its ROS1-targeted lung cancer therapy IBTROZI, a 25% sequential increase. Approximately 160 patients began treatment during the period, with about 85% of new starts in the first-line setting, up from roughly 30% at launch. The company also announced an expanded clinical development plan for safusidenib in IDH1-mutant glioma, citing updated Phase II data showing a 52% objective response rate and a 79% three-year progression-free survival rate, and adding a randomized Phase III trial and a Phase II study in earlier-stage and post-vorasidenib patients. Nuvation held $661 million in cash and marketable securities as of June 30 and raised approximately $279.1 million in net proceeds through a convertible notes offering, which management said should support operations through profitability and the anticipated safusidenib launch.

Nuvation Bio announced that the UK drug regulator has accepted the marketing application for its lung cancer drug taletrectinib, which targets advanced ROS1-positive non-small cell lung cancer. The application was submitted by Nuvation Bio's partner Eisai. The drug has already secured marketing approvals in the US, Japan, and China, and the company is now seeking approval in the UK and other international markets. Nuvation Bio exited the first quarter of 2026 with 533.7 million dollars in cash, cash equivalents, and marketable securities, and recently raised 287.5 million dollars through a notes offering.

Nuvation Bio announced that its partner Eisai's Marketing Authorisation Application for taletrectinib in advanced ROS1-positive non-small cell lung cancer was validated by the U.K. MHRA under the International Recognition Procedure. This adds to an already validated application with the European Medicines Agency and planned filings in Canada and other regions. Taletrectinib is already approved as IBTROZI in the U.S., Japan and China, and this regulatory momentum could extend Nuvation Bio's reach into additional ROS1-positive lung cancer markets through Eisai's licensed territories. The company recently raised US$250.0 million in convertible notes due 2032 to fund international filings and long-running glioma studies, though this adds potential future dilution. Analysts project Nuvation Bio could reach $427.2 million in revenue and $5.2 million in earnings by 2028, requiring 151.8% yearly revenue growth.

Dr. David Hung, CEO and founder of Nuvation Bio, shared his dealmaking strategies, highlighting the company's strong financial position after first quarter revenue exceeded analyst expectations by nearly 26%. Hung, who previously sold his startup Medivation to Pfizer in a $14 billion deal, emphasized the importance of a cash runway and objective data evaluation. Nuvation Bio's recent acquisition of AnHeart Therapeutics brought in Ibtrozi, a kinase inhibitor approved for non-small-cell lung cancer, and safusidenib, a drug targeting mutant IDH1 in brain tumors that showed 87.9% progression-free survival at 24 months in a phase 2 study. The AnHeart deal was structured as an all-stock transaction giving AnHeart shareholders 33% of the company, and Nuvation also used royalty financing, selling 5% of Ibtrozi U.S. sales valued at $3 billion to secure $150 million plus a $100 million loan. Hung noted the company is now well capitalized with a market cap over $2 billion and is running pivotal studies for safusidenib.

Nuvation Bio Director Robert Mashal acquired 25,000 shares of the clinical-stage oncology biotech through an open-market transaction on June 9, 2026, according to an SEC filing. The purchase, valued at $118,250 based on a reported price of $4.73 per share, raises his indirect holdings via a trust to 225,000 shares while his direct holdings remain at zero. The transaction occurred as Nuvation Bio shares closed at $4.93 on the trade date, reflecting a 96% gain over the prior year, and follows the July 2025 launch of its first FDA-approved product, Ibtrozi, for non-small cell lung cancer. Wall Street projects the company's revenue will reach nearly $203 million this year, up from almost $63 million in 2025.